COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN GERMANY

被引：0
|
作者：
von Depka, M. [1 ]
Salama, A. [2 ]
Perrin, A. [3 ]
Oelze, I. [3 ]
Chulikavit, M. [3 ]
Kunz, E. [4 ]
Kutikova, L. [4 ]
Thalheimer, M. [5 ]
机构：
[1] Werlhof Inst, Hannover, Germany
[2] Charite Univ Med Berlin, Inst Transfus Med, Berlin, Germany
[3] Analyt LA SER Int Inc, New York, NY USA
[4] Amgen GmbH, Munich, Germany
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1045
引用
收藏
页码：427 / 427
页数：1
相关论文
共 50 条
  • [1] COST-CONSEQUENCE ANALYSIS COMPARING ROMIPLOSTIM TO RITUXIMAB IN THE TREATMENT OF ADULT PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN FRANCE
    Chiche, L.
    Lefrere, F.
    Chulikavit, M.
    Perrin, A.
    Stern, L.
    Bischof, M.
    Cohen, S.
    VALUE IN HEALTH, 2011, 14 (07) : A415 - A415
  • [2] Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia (ITP) in France Abstracts (vol 14, pg A415, 2011)
    Chiche, Laurent
    Lefrere, Francois
    Chulikavit, Maruit
    Perrin, Allison
    Stern, Lee
    Bischof, Matthias
    Cohen, Sandra
    VALUE IN HEALTH, 2012, 15 (01) : 213 - 213
  • [3] Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 705 - 713
  • [4] Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain
    Fernanda Lopez, M.
    Eva Mingot, Maria
    Valcarcel, David
    Vicente Garcia, Vicente
    Perrin, Allison
    Campos Tapias, Ignasi
    MEDICINA CLINICA, 2015, 144 (09): : 389 - 396
  • [5] Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
    Tremblay, Gabriel
    Dolph, Mike
    Bhor, Menaka
    Said, Qayyim
    Roy, Anuja
    Elliott, Brian
    Briggs, Andrew
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2018, 10 : 715 - 721
  • [6] Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France
    Chiche, L.
    Perrin, A.
    Stern, L.
    Kutikova, L.
    Cohen-Nizard, S.
    Lefrere, F.
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2014, 21 (02) : 85 - 93
  • [7] Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia
    Tremblay, Gabriel
    Bhor, Menaka
    Roy, Anuja
    Elliott, Brian
    Dolph, Mike
    Forsythe, Anna
    Briggs, Andrew
    BLOOD, 2017, 130
  • [8] COST CONSEQUENCE MODEL COMPARING ELTROMBOPAG AND ROMIPLOSTIM FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED CHRONIC IMMUNE THROMBOCYTOPENIA
    Tremblay, G.
    Dolph, M.
    Bhor, M.
    Elliott, B.
    VALUE IN HEALTH, 2017, 20 (05) : A220 - A220
  • [9] COST EFFECTIVENESS OF ROMIPLOSTIM FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA (ITP) PATIENTS IN THE CZECH REPUBLIC
    Brezina, T.
    Klimes, J.
    Dolezal, T.
    Maskova, H.
    Campioni, M.
    Kutikova, L.
    VALUE IN HEALTH, 2014, 17 (07) : A533 - A533
  • [10] Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP)
    Wasser, Jeffrey
    Boccia, Ralph Vincent V.
    Lyons, Roger M.
    Mandanas, Romeo
    Pabinger, Ingrid
    Michel, Marc
    Viallard, Jean-Francois
    Wang, Xuena
    Lizambri, Richard
    BLOOD, 2011, 118 (21) : 1411 - 1412
12345